 |
Indication & Dosage |
| |
| |
| Intravenous |
| WILM'S TUMOUR, EWING'S SARCOMA AND CHILDHOOD RHABDOMYOSARCOMA |
| Child:
>6 mth: 15 mcg/kg/day or 400-600 mcg/m2 BSA/day. To be given for 5 days per 2-wk cycle. |
| |
| Intravenous |
| WILM'S TUMOUR, EWING'S SARCOMA AND CHILDHOOD RHABDOMYOSARCOMA |
| Adult:
15 mcg/kg/day or 400-600 mcg/m2 BSA/day for 5 days. |
| |
| Intravenous |
| GESTATIONAL TROPHOBLASTIC TUMOURS |
| Adult:
12 mcg/kg/day for 5 days as a single agent or 500 mcg/day on days 1 and 2 of combination regimens. |
| |
| Intravenous |
| METASTATIC NONSEMINOMATOUS TESTICULAR CANCER |
| Adult:
1 mg/m2 on day 1 of combination regimens. |
|
| |
|
| Precautions |
Admin drug with care to avoid extravsasation. GI toxicity and bone marrow suppression has been reported when given with x-ray therapy. Increased risk of hepatomegaly and elevated SGOT levels when administering within 2 mth of irradiation for the treatment of right-sided Wilms' tumor. Discontinue drug if stomatitis, diarrhoea or severe haematopoietic depression results, until patient recovers. Monitor renal, hepatic and bone marrow functions regularly. Pregnancy. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Cheilitis, dysphagia, oesophagitis, ulcerative stomatitis, pharyngitis; anorexia, nausea, vomiting, abdominal pain, diarrhoea, GI tract ulceration; liver toxicity including ascites, hepatomegaly, hepatitis, LFT abnormalities; anaemia, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, reticulopenia, alopoecia; skin eruptions, acne, flare-up of erythema or increased pigmentation of previously irradiated skin. If extravasation occurs during IV use, it leads to severe damage of soft tissues. Malaise, fatigue, lethargy, fever, myalgia, proctitis and hypocalcaemia. |
| |
|
| Adverse Drug Reactions |
Veno-occlusive disease (primarily hepatic) may result in fatality especially in children <48 mth. |
| |
|
|
|
